Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): Old target-new inhibition mode

Eva Bligt-Lindén, Marjo Pihlavisto, István Szatmári, Zbyszek Otwinowski, David J. Smith, László Lázár, Ferenc Fülöp, Tiina A. Salminen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Vascular adhesion protein-1 (VAP-1) is a primary amine oxidase and a drug target for inflammatory and vascular diseases. Despite extensive attempts to develop potent, specific, and reversible inhibitors of its enzyme activity, the task has proven challenging. Here we report the synthesis, inhibitory activity, and molecular binding mode of novel pyridazinone inhibitors, which show specificity for VAP-1 over monoamine and diamine oxidases. The crystal structures of three inhibitor-VAP-1 complexes show that these compounds bind reversibly into a unique binding site in the active site channel. Although they are good inhibitors of human VAP-1, they do not inhibit rodent VAP-1 well. To investigate this further, we used homology modeling and structural comparison to identify amino acid differences, which explain the species-specific binding properties. Our results prove the potency and specificity of these new inhibitors, and the detailed characterization of their binding mode is of importance for further development of VAP-1 inhibitors.

Original languageEnglish (US)
Pages (from-to)9837-9848
Number of pages12
JournalJournal of Medicinal Chemistry
Volume56
Issue number24
DOIs
StatePublished - Dec 27 2013

Fingerprint

Blood Vessels
Proteins
Amine Oxidase (Copper-Containing)
Monoamine Oxidase
Enzyme Inhibitors
Vascular Diseases
Amines
Rodentia
Catalytic Domain
Oxidoreductases
Binding Sites
Amino Acids
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Bligt-Lindén, E., Pihlavisto, M., Szatmári, I., Otwinowski, Z., Smith, D. J., Lázár, L., ... Salminen, T. A. (2013). Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): Old target-new inhibition mode. Journal of Medicinal Chemistry, 56(24), 9837-9848. https://doi.org/10.1021/jm401372d

Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1) : Old target-new inhibition mode. / Bligt-Lindén, Eva; Pihlavisto, Marjo; Szatmári, István; Otwinowski, Zbyszek; Smith, David J.; Lázár, László; Fülöp, Ferenc; Salminen, Tiina A.

In: Journal of Medicinal Chemistry, Vol. 56, No. 24, 27.12.2013, p. 9837-9848.

Research output: Contribution to journalArticle

Bligt-Lindén, E, Pihlavisto, M, Szatmári, I, Otwinowski, Z, Smith, DJ, Lázár, L, Fülöp, F & Salminen, TA 2013, 'Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): Old target-new inhibition mode', Journal of Medicinal Chemistry, vol. 56, no. 24, pp. 9837-9848. https://doi.org/10.1021/jm401372d
Bligt-Lindén, Eva ; Pihlavisto, Marjo ; Szatmári, István ; Otwinowski, Zbyszek ; Smith, David J. ; Lázár, László ; Fülöp, Ferenc ; Salminen, Tiina A. / Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1) : Old target-new inhibition mode. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 24. pp. 9837-9848.
@article{93958eea94a44aaeabfc4c568b13cb71,
title = "Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): Old target-new inhibition mode",
abstract = "Vascular adhesion protein-1 (VAP-1) is a primary amine oxidase and a drug target for inflammatory and vascular diseases. Despite extensive attempts to develop potent, specific, and reversible inhibitors of its enzyme activity, the task has proven challenging. Here we report the synthesis, inhibitory activity, and molecular binding mode of novel pyridazinone inhibitors, which show specificity for VAP-1 over monoamine and diamine oxidases. The crystal structures of three inhibitor-VAP-1 complexes show that these compounds bind reversibly into a unique binding site in the active site channel. Although they are good inhibitors of human VAP-1, they do not inhibit rodent VAP-1 well. To investigate this further, we used homology modeling and structural comparison to identify amino acid differences, which explain the species-specific binding properties. Our results prove the potency and specificity of these new inhibitors, and the detailed characterization of their binding mode is of importance for further development of VAP-1 inhibitors.",
author = "Eva Bligt-Lind{\'e}n and Marjo Pihlavisto and Istv{\'a}n Szatm{\'a}ri and Zbyszek Otwinowski and Smith, {David J.} and L{\'a}szl{\'o} L{\'a}z{\'a}r and Ferenc F{\"u}l{\"o}p and Salminen, {Tiina A.}",
year = "2013",
month = "12",
day = "27",
doi = "10.1021/jm401372d",
language = "English (US)",
volume = "56",
pages = "9837--9848",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "24",

}

TY - JOUR

T1 - Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1)

T2 - Old target-new inhibition mode

AU - Bligt-Lindén, Eva

AU - Pihlavisto, Marjo

AU - Szatmári, István

AU - Otwinowski, Zbyszek

AU - Smith, David J.

AU - Lázár, László

AU - Fülöp, Ferenc

AU - Salminen, Tiina A.

PY - 2013/12/27

Y1 - 2013/12/27

N2 - Vascular adhesion protein-1 (VAP-1) is a primary amine oxidase and a drug target for inflammatory and vascular diseases. Despite extensive attempts to develop potent, specific, and reversible inhibitors of its enzyme activity, the task has proven challenging. Here we report the synthesis, inhibitory activity, and molecular binding mode of novel pyridazinone inhibitors, which show specificity for VAP-1 over monoamine and diamine oxidases. The crystal structures of three inhibitor-VAP-1 complexes show that these compounds bind reversibly into a unique binding site in the active site channel. Although they are good inhibitors of human VAP-1, they do not inhibit rodent VAP-1 well. To investigate this further, we used homology modeling and structural comparison to identify amino acid differences, which explain the species-specific binding properties. Our results prove the potency and specificity of these new inhibitors, and the detailed characterization of their binding mode is of importance for further development of VAP-1 inhibitors.

AB - Vascular adhesion protein-1 (VAP-1) is a primary amine oxidase and a drug target for inflammatory and vascular diseases. Despite extensive attempts to develop potent, specific, and reversible inhibitors of its enzyme activity, the task has proven challenging. Here we report the synthesis, inhibitory activity, and molecular binding mode of novel pyridazinone inhibitors, which show specificity for VAP-1 over monoamine and diamine oxidases. The crystal structures of three inhibitor-VAP-1 complexes show that these compounds bind reversibly into a unique binding site in the active site channel. Although they are good inhibitors of human VAP-1, they do not inhibit rodent VAP-1 well. To investigate this further, we used homology modeling and structural comparison to identify amino acid differences, which explain the species-specific binding properties. Our results prove the potency and specificity of these new inhibitors, and the detailed characterization of their binding mode is of importance for further development of VAP-1 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84891316808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891316808&partnerID=8YFLogxK

U2 - 10.1021/jm401372d

DO - 10.1021/jm401372d

M3 - Article

C2 - 24304424

AN - SCOPUS:84891316808

VL - 56

SP - 9837

EP - 9848

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 24

ER -